Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses

Debin, Arnaud; Kravtzoff, Roger; Santiago, Jocelyn Vaz; Cazales, Laurence; Spérandio, S; Melber, Karl; Janowicz, Zbigniew A.; Betbeder, Didier; Moynier, Marinette

doi:10.1016/s0264-410x(02)00191-3

Cited by 101 publications

(57 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low bioavailability obtained can be due to the fact that particles are probably taken up by M-cells in the nasal associated lymphoid tissue and, therefore, transported into the lymphatic system and blood stream (35, 98). In contrast, other studies have suggested that nanoparticle systems may be ideally suited for the delivery of nasal vaccines (76,(169)(170)(171).…”

Section: Nanoparticlesmentioning

confidence: 95%

Intranasal Drug Delivery: How, Why and What for?

2009

View full text Add to dashboard Cite

Over the recent decades the interest in intranasal delivery as a non-invasive route for drugs is increased. Since the nasal mucosa offers numerous benefits as a target tissue for drug delivery, a wide variety of therapeutic compounds may be administered intranasally for topic, systemic and central nervous system action. We have, herein, outlined the relevant aspects of nasal anatomy, physiology and histology, and the biological, physicochemical and pharmaceutical factors that must be considered during the process of discovery and development of nasal drugs as well as in their incorporation into appropriate nasal pharmaceutical formulations. _______________________________________________________________________________________

show abstract

Section: Nanoparticlesmentioning

confidence: 95%

Intranasal Drug Delivery: How, Why and What for?

2009

View full text Add to dashboard Cite

show abstract

“…The significance of the predominance of anti-PA IgG1 induced by vaccination in humans is not clear but is consistent with responses observed following the administration of tetanus toxoid (51). Anti-PA IgA antibodies have been detected in mice immunized intranasally with PA-containing preparations but not in mice vaccinated intradermally or subcutaneously (11,17). Humans, rhesus macaques, and rabbits vaccinated with cell-free anthrax vaccines intramuscularly or subcutaneously are not likely to produce significant quantities of anti-PA IgA (11,30).…”

Section: Immune Responses and Correlates Of Protection Humoral Immunitymentioning

confidence: 99%

Rabbit and Nonhuman Primate Models of Toxin-Targeting Human Anthrax Vaccines

Phipps

Premanandan

Barnewall

et al. 2004

Microbiol Mol Biol Rev

View full text Add to dashboard Cite

The intentional use of Bacillus anthracis, the etiological agent of anthrax, as a bioterrorist weapon in late 2001 made our society acutely aware of the importance of developing, testing, and stockpiling adequate countermeasures against biological attacks. Biodefense vaccines are an important component of our arsenal to be used during a biological attack. However, most of the agents considered significant threats either have been eradicated or rarely infect humans alive today. As such, vaccine efficacy cannot be determined in human clinical trials but must be extrapolated from experimental animal models. This article reviews the efficacy and immunogenicity of human anthrax vaccines in well-defined animal models and the progress toward developing a rugged immunologic correlate of protection. The ongoing evaluation of human anthrax vaccines will be dependent on animal efficacy data in the absence of human efficacy data for licensure by the U.S. Food and Drug Administration

show abstract

“…The nasal, vaginal and salivary secretions were collected on 0 and 42 d of primary vaccination. Vaginal washes were obtained according to the method given by Debin et al (2002). Briefly, the vaginal tracts of non-anaesthetized mice were flushed by reintroducing 50 mL of PBS containing 1% (w/v) BSA using a Gilson pipette.…”

Section: Sample Collectionmentioning

confidence: 99%

Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response

Pawar

Jaganathan

2014

Drug Delivery

View full text Add to dashboard Cite

In this study, for the first time, glycol chitosan (GC) nanoparticles (NPs) were prepared and evaluated to obtain systemic and mucosal immune responses against nasally administered hepatitis B surface antigen (HBsAg). Size, zeta potential and morphology of the NPs were investigated as a function of preparation method. NPs with high loading efficacy (495%) and positively charged surface were obtained with an average particle size of approximately 200 nm. The structural integrity of HBsAg in NPs was evaluated by sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis and further confirmed by measuring the in vitro antigenicity using an enzyme immunoassay. During in vivo studies, GC NPs showed the lowest nasal clearance rate and better mucosal uptake when compared with chitosan (CS) NPs. The immunogenicity of NPs-based delivery system(s) was assessed by measuring anti-HBsAg antibody titer in mice serum and secretions after intranasal administration. The alum-based HBsAg vaccine injected subcutaneously was used as positive control. Results indicated that alum-based HBsAg induced strong humoral but negligible mucosal immunity. However, GC NPs induced stronger immune response at both of the fronts as compared to generated by CS NPs. This study demonstrates that this newly developed system has potential for mucosal administration of vaccines.

show abstract

Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses

Cited by 101 publications

References 58 publications

Intranasal Drug Delivery: How, Why and What for?

Intranasal Drug Delivery: How, Why and What for?

Rabbit and Nonhuman Primate Models of Toxin-Targeting Human Anthrax Vaccines

Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response

Contact Info

Product

Resources

About